Peptides

Compound profiles, from the studies up

Each profile reports what cited studies found, the doses those studies administered, the side effects they recorded, and where the compound stands with U.S. regulators. Nothing here is a recommendation.

GLP-1 and related metabolic peptides

Semaglutide, tirzepatide, retatrutide, cagrilintide: incretin-pathway compounds studied for weight and glucose.

GLP-1 and related metabolic peptidesCagrilintideCagrilintide is a long-acting amylin analogue studied as a once-weekly subcutaneous injection for weight management, alone and coformulated with semaglutide as CagriSema. A phase 2 dose-finding trial reported greater weight loss than placebo, and phase 3 REDEFINE and REIMAGINE trials reported large weight and HbA1c reductions with the combination. Gastrointestinal adverse events were common. Cagrilintide is not an FDA-approved drug.

Peptide15 human studies

Tissue repair and recovery

BPC-157, TB-500, KPV: compounds studied mostly in animal models of injury and inflammation.

Tissue repair and recoveryBPC-157BPC-157 is a synthetic pentadecapeptide described as a partial sequence of a compound isolated from human gastric juice. Nearly all published evidence is preclinical: rat models of tendon, muscle, gut and skin injury. Human data are limited to a few small uncontrolled pilot reports, and randomized trials are only now registered. It is not an FDA-approved drug.

Peptide7 human studies